Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is P&G’s pharma business for sale?

Executive Summary

A sale of Procter & Gamble's pharma business could fetch more than $1 billion, according to an estimate by one analyst. That's revenue P&G could reinvest in its core business areas, beauty and consumer health care. Reports that P&G's Rx business is up for sale began circulating the week of Feb. 2. Sources say the company has indeed hired Goldman Sachs to facilitate a sale of the business, although P&G dismissed the reports as "total speculation." News of a potential sale hardly comes as a surprise after P&G announced in December that the company was halting investment in pharmaceuticals and reducing headcount in its 2,900-person pharmaceutical workforce by 6 percent to 7 percent to focus on more profitable businesses, including oral care and consumer health care (1"The Pink Sheet," Dec. 22, 2008, p. 9). Potential buyers could include P&G's existing partners: Sanofi-Aventis on Actonel and Novartis on Enablex

You may also be interested in...

P&G Exits Drug R&D in Favor of Consumer Healthcare

Procter & Gamble is moving away from pharmaceuticals to focus on more profitable businesses, such as oral care and consumer healthcare

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts